# GE Healthcare acquires oncology biomarker maker Zionexa

GE Healthcare acquired France-based Zionexa to develop and commercialize molecular imaging agents for cancer treatment, including Cerianna.

- Type: Acquisition
- Announced: 2021-05-07
- Where: France
- Status: completed
- Products: Cerianna (fluoroestradiol F-18) PET imaging agent, oncology biomarkers
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [GE Healthcare](https://endata.com/companies/4246.md) (acquirer)
- [Zionexa](https://endata.com/companies/54977.md) (target)

## Sources

- [medicaldevice-network.com](https://www.medicaldevice-network.com/news/ge-healthcare-acquires-zionexa/), 2021-05-07: "This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.